TherapeuticsMD, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TXMD research report →
Companywww.therapeuticsmd.com
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.
- CEO
- Marlan D. Walker
- IPO
- 2007
- Employees
- 1
- HQ
- Boca Raton, FL, US
Price Chart
Valuation
- Market Cap
- $24.07M
- P/E
- 134.49
- P/S
- 7.18
- P/B
- 0.89
- EV/EBITDA
- -5.51
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.31%
- Op Margin
- -111.66%
- Net Margin
- 5.34%
- ROE
- 0.66%
- ROIC
- -8.35%
Growth & Income
- Revenue
- $3.02M · 71.61%
- Net Income
- $-569,000 · 73.91%
- EPS
- $-0.05 · 74.11%
- Op Income
- $-4,214,000
- FCF YoY
- 231.15%
Performance & Tape
- 52W High
- $2.95
- 52W Low
- $0.98
- 50D MA
- $2.11
- 200D MA
- $1.72
- Beta
- 0.58
- Avg Volume
- 21.94K
Get TickerSpark's AI analysis on TXMD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 23, 25 | Thompson Tommy G | buy | 8,400 |
| Nov 3, 25 | Thompson Tommy G | other | 8,500 |
| Nov 3, 25 | Naughton Gail K | other | 8,500 |
| Nov 3, 25 | Collins Cooper C. | other | 8,500 |
| Nov 3, 25 | Walker Marlan D | other | 67,492 |
| Apr 14, 25 | Thompson Tommy G | buy | 325 |
| Apr 14, 25 | Walker Marlan D | buy | 490 |
| Apr 10, 25 | Walker Marlan D | buy | 1,167 |
| Apr 9, 25 | Walker Marlan D | buy | 1,136 |
| Feb 18, 25 | Collins Cooper C. | other | 8,500 |
Our TXMD Coverage
We haven't published any research on TXMD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TXMD Report →